Biomarker: PD-L1

Country: Germany

Region: Bonn

Followed up time :

Conclusion: In EC, PD-L1 expression has no prognostic significance, but correlates with other oncogenic factors and indicates increased infiltration of the tumor with immune cells. Thus, PD-1/PD-L1 immunecheckpoint blockade seems to be very promising, at least in a subset of EC patients.

Sample type : tissue

Sample method: immunocytochemical staining

Expression pattern : expression

Expression elevation: PD-L1 staining of tumor cells was considered positive when continuous staining of cell membranes was observed. The classification of the degree of staining was divided into the four categories 0 (no staining), 1+ (mild staining), 2+ (moderate staining), and 3+ (strong staining; Figure 1A-D). In addition, the percentage of stained tumor cells was estimated. Tumor areas with a staining intensity of ≥1+ with a percentage of ≥1% of tumor cells were considered positive

Statictics: Median;Mean (SD)

Cohort age: 63.6,33.0-89.2

Funtion Uniprot: Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).4 Publications The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

UniProt ID: Q9NZQ7

UniProt Link: https://www.uniprot.org/uniprotkb/Q9NZQ7/entry

Biological function from UniProt: #Adaptive immunity #Immunity

Molecular function from UniProt:

Tissue specificity from UniProt: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

Subcellular UniProt: #Cell membrane #Endosome #Membrane

Alternative name from UniProt:

Recommended name: Programmed cell death 1 ligand 1

Gene name from HGNC: CD274 (B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1)

CD antigen name: CD274

HPA class: Cancer-related genes CD markers Disease related genes FDA approved drug targets

AlphaFold DB: Q9NZQ7

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q9NZQ7

Induction: Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking.

HPA link: https://www.proteinatlas.org/ENSG00000120217-CD274

Tissue specificity RNA from HPA: Tissue enhanced (lung)

Tissue expression from HPA: High expression in placental trophoblasts.

Single cell type specificity Group enriched (Langerhans cells, Syncytiotrophoblasts, granulocytes, Extravillous trophoblasts)

Immune cell specificity: Immune cell enhanced (basophil)

Subcellular summary HPA Localized to the Plasma membrane, Actin filaments In addition localized to the Nucleoplasm

Cancer prognostic summary HPA Prognostic marker in colorectal cancer (favorable) and breast cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000120217-CD274/pathology/endometrial+cancer

Disease: No disease ID

Note1: Truncation of the 3'-untranslated (3'-UTR) region of CD274 transcripts leads to elevated expression of CD274 in multiple cancers including T-cell leukemia, diffuse large B-cell lymphoma and stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region is caused by structural variants that stabilize CD274 transcripts, leading to overexpression (PubMed:27281199). Increased expression in tumors promotes immune evasion and tumor cell growth by allowing malignant cells to escape destruction by the immune system (PubMed:27281199)

OMIM: 605402

OMIM link2: https://www.omim.org/entry/605402

HGNC ID: HGNC:17635

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635